STOCK TITAN

Ekso Bionics (NASDAQ: EKSO) holder discloses 9.48% stake in Schedule 13G

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Ekso Bionics Holdings, Inc. received a Schedule 13G reporting a significant ownership position in its ordinary shares. Investor Daniel Asher reports beneficial ownership of 321,763 shares, representing 9.48% of the class, with shared power to vote and dispose of these shares and no sole voting or dispositive power.

Related entity DBA Trading, LLC is identified as a reporting person with shared voting and dispositive power over 156,763 shares and a stated 4.62% of the class. The filing states that Asher is the beneficial owner of DBA Trading, LLC and is deemed to control voting and dispositive power over the shares held by that entity. The certification notes that the securities are not held for the purpose of changing or influencing control of Ekso Bionics.

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What ownership stake in Ekso Bionics (EKSO) does Daniel Asher report?

Daniel Asher reports beneficial ownership of 321,763 Ekso Bionics ordinary shares, representing 9.48% of the outstanding class, with shared voting and dispositive power.

Who are the reporting persons in this Ekso Bionics Schedule 13G filing?

The reporting persons are Daniel Asher and DBA Trading, LLC. Asher is identified as the beneficial owner of DBA Trading, LLC and is deemed to control voting and dispositive power over shares held by that entity.

How many Ekso Bionics shares are associated with DBA Trading, LLC?

DBA Trading, LLC is reported as having shared voting and dispositive power over 156,763 Ekso Bionics shares, and this position is stated as representing 4.62% of the class.

Is this Ekso Bionics (EKSO) ownership filing intended to influence control of the company?

The certification states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Ekso Bionics, and are not held in connection with any transaction having that purpose or effect.

What type of securities are covered in this Ekso Bionics Schedule 13G?

The filing covers ordinary shares of Ekso Bionics Holdings, Inc. with a nominal value of $0.01 per share, identified by CUSIP number 282644400.

What is the date of the event that triggered this Ekso Bionics Schedule 13G?

The date of the event requiring the filing is listed as December 30, 2025.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



DANIEL ASHER
Signature:/s/ Daniel Asher
Name/Title:Daniel Asher
Date:01/08/2026
DBA Trading, LLC
Signature:/s/ Fred Goldman
Name/Title:Fred Goldman, Member
Date:01/08/2026
Exhibit Information

99.1 Joint Filing Agreement of the Reporting Persons 99.2 Transactions of the Reporting Persons